Coya Therapeutics, Inc. - Common Stock (NQ:COYA)

4.930 +0.120 (+2.49%)

Delayed Quote Updated: 2:16 PM EDT, Oct 5, 2026 Add to My Watchlist

Quote

Overview Detailed Quote Charting Historical Prices

News

All News News Headlines Press Releases

Research

Quarterly Reports Insider Filings Other Filings

All News about Coya Therapeutics, Inc. - Common Stock

< Previous 1 2 3 4 5 6 7 Next >

Coya Therapeutics Congratulates Scientific Advisor Dr. Shimon Sakaguchi for Receiving The Nobel Prize in Physiology or Medicine for Discovery of Regulatory T Cells and Immune Function

October 07, 2025

From Coya Therapeutics, Inc.

Via Business Wire

EXCLUSIVE: Coya Therapeutics Investigational Combination Therapy With GLP-1 Shows Potential For Alzheimer's Disease ↗

September 16, 2025

Coya's COYA 303 showed strong immune modulation and reduced inflammation in the brain, supporting its development for neurodegenerative diseases like Alzheimer's.

Via Benzinga

12 Health Care Stocks Moving In Monday's After-Market Session ↗

August 25, 2025

Via Benzinga

What's Going On With Coya Therapeutics Stock? ↗

August 25, 2025

Shares of Coya Therapeutics are trading higher Monday morning. The company provided an update regarding the development of a new treatment for Amyotrophic Lateral Sclerosis.

Via Benzinga

12 Health Care Stocks Moving In Monday's Pre-Market Session ↗

August 25, 2025

Via Benzinga

Coya Therapeutics Announces Publication of Scientific Research Linking Inflammation and Oxidative Stress to the Progression of Parkinson’s Disease

July 24, 2025

From Coya Therapeutics, Inc.

Via Business Wire

Coya Therapeutics to Participate in the BTIG Virtual Biotechnology Conference July 29 – 30, 2025

July 22, 2025

From Coya Therapeutics, Inc.

Via Business Wire

Updated Lineup Announced for iAccess Alpha's Virtual Summer Investment Conference, June 24–25, 2025

June 23, 2025

Via ACCESS Newswire

iAccess Alpha's Virtual Best Ideas Summer Investment Conference June 24-25, 2025

June 18, 2025

Via ACCESS Newswire

Coya Therapeutics to Present at the iAccess Alpha Virtual Best Ideas Summer Conference on June 24 – 25, 2025

June 18, 2025

From Coya Therapeutics, Inc.

Via Business Wire

Coya Therapeutics Announces Issuance of New U.S. Patent Protecting Methods of Producing Recombinant Human (rh) Interleukin-2 (aldesleukin) Liquid Formulations

June 02, 2025

From Coya Therapeutics, Inc.

Via Business Wire

Coya Therapeutics to Participate at the H.C. Wainwright 3rd Annual BioConnect Investor Conference

May 16, 2025

From Coya Therapeutics, Inc.

Via Business Wire

Coya Therapeutics Reports First Quarter Financial Results and Provides a Corporate Update

May 13, 2025

From Coya Therapeutics, Inc.

Via Business Wire

Coya Therapeutics to Participate in Two Upcoming Conferences in May 2025

May 08, 2025

From Coya Therapeutics, Inc.

Via Business Wire

Why Meta Shares Are Trading Higher By Around 6%; Here Are 20 Stocks Moving Premarket ↗

May 01, 2025

Via Benzinga

Coya Therapeutics Announce Positive Interim Result from Investigator-Initiated Open Label Study with Low-Dose IL-2 and CTLA4-Ig Treatment in Five Patients with Mild to Moderate Frontotemporal Dementia

April 24, 2025

Via Get News

Coya Therapeutics Announces Positive Interim Results of an Investigator-Initiated Open Label Study with Low-Dose IL-2 and CTLA4-Ig Combination Treatment in Five Patients with Mild to Moderate Frontotemporal Dementia

April 24, 2025

From Coya Therapeutics, Inc.

Via Business Wire

Coya Therapeutics Announces Publication of GLP-1/LD IL-2 Combination Biologic (COYA 303) Demonstrating Synergistic Enhancement of Regulatory T Cell Function and Protection Against Treg Apoptosis (Cell Death)

April 21, 2025

From Coya Therapeutics, Inc.

Via Business Wire

Atea Pharmaceuticals Appoints Howard H. Berman to Board of Directors and Announces Share Repurchase Program

April 17, 2025

Enters into Agreement with Bradley L. Radoff and Michael Torok

From Atea Pharmaceuticals, Inc.

Via GlobeNewswire

12 Health Care Stocks Moving In Thursday's After-Market Session ↗

April 03, 2025

Via Benzinga

Coya Therapeutics Selected for Platform Presentation at the ADPD 2025 Conference in Vienna on April 5, 2025

April 01, 2025

From Coya Therapeutics, Inc.

Via Business Wire

Coya Therapeutics Reports Progress from an Academic Supported First-in-Class Treg-derived Exosome Program

March 26, 2025

From Coya Therapeutics, Inc.

Via Business Wire

Coya Therapeutics Provides a Corporate Update and Reports Fiscal 2024 Financial Results

March 18, 2025

From Coya Therapeutics, Inc.

Via Business Wire

12 Health Care Stocks Moving In Friday's After-Market Session ↗

March 14, 2025

Via Benzinga

Coya Therapeutics to Participate in KOL Call Hosted by BTIG to Discuss the Potential Treatment of Alzheimer’s Disease Using GLP-1 Agonists and Combinations

February 25, 2025

From Coya Therapeutics, Inc.

Via Business Wire

Coya Therapeutics' Alzheimer's Candidate Shows Improved Inflammatory Blood Markers Following Monthly Dosing ↗

February 06, 2025

Coya Therapeutics' Phase 2 study shows monthly LD IL-2 improves cognitive scores and reduces inflammation in Alzheimer's patients, with no serious adverse events.

Via Benzinga

Coya Therapeutics Reports Statistically Significant Improvement of Inflammatory Blood Markers in Patients with Alzheimer’s Disease Following Monthly Dosing with Low-Dose IL-2, Further Supporting Clinical Development

February 06, 2025

From Coya Therapeutics, Inc.

Via Business Wire

Coya Therapeutics to Present at the Oppenheimer 35th Annual Healthcare Life Sciences Conference

February 04, 2025

From Coya Therapeutics, Inc.

Via Business Wire

Coya Therapeutics Announces Pipeline Expansion - COYA 303: COYA 301 in Combination with GLP-1 Receptor Agonist for the Treatment of Inflammatory Diseases

January 21, 2025

From Coya Therapeutics, Inc.

Via Business Wire

EXCLUSIVE: Coya Therapeutics Expands Its Pipeline With Combo Therapy For Inflammatory Diseases ↗

January 21, 2025

Coya Therapeutics advances COYA 303 for inflammatory diseases, combining COYA 301 and GLP-1 RA for a synergistic anti-inflammatory effect.

Via Benzinga

< Previous 1 2 3 4 5 6 7 Next >

Stock Quote API & Stock News API supplied by www.cloudquote.io. Quotes delayed at least 20 minutes. Market data may be delayed. Research information, not personalized advice.